Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Former Australian soldier arrested over alleged Afghan war crimes - 2Well known SUVs With Low Energy Utilization In 2024 vote
- 3Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- 4Several injured as man threatens attack on German high-speed train
- 5Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- An Aide On Upgrading Your FICO rating
- Intriguing Strange Cruising Objections you Should Visit
- Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene
- Discovering a true sense of harmony: Contemplation and Care Practices
- IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
- 'The Secret Lives of Mormon Wives' Season 3 premieres tomorrow. Here's what you need to know to catch up.
- Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
- CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
